Efficacy and safety of simvastatin (alone or in association with cholestyramine). A 1-year study in 66 patients with type II hyperlipoproteinaemia.

  title={Efficacy and safety of simvastatin (alone or in association with cholestyramine). A 1-year study in 66 patients with type II hyperlipoproteinaemia.},
  author={J. Emmerich and I. Aubert and B. Bauduceau and C. Dachet and B. Chanu and D. Erlich and D. Gautier and B. Jacotot and J. Rouffy},
  journal={European heart journal},
  volume={11 2},
The effects and safety of simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, were investigated alone or in association with cholestyramine in 66 patients with hypercholesterolaemia, in a 1-year study. In type IIa hypercholesterolaemia (41 patients), the association was more effective than simvastatin used alone in lowering total cholesterol (37% vs 29%) and LDL-cholesterol (45% vs 37%). In type IIb hypercholesterolaemia (23 patients), the association simvastatin… Expand
Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia.
If further study confirms long term tolerability and an impact on cardiac mortality and morbidity, then simvastatin and others of its class should offer a significant new approach to the treatment of hypercholesterolaemia. Expand
An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor.
The safety profile of atorvastatin was consistent with that of all statins tested and was similar to that seen in all compounds of this class. Expand
Long Term Treatment with Pravastatin, Simvastatin and Gemfibrozil in Patients with Primary Hypercholesterolaemia: A Controlled Study
It would appear that gemfibrozil is an effective lipid-lowering agent which is suitable for long term treatment, although this finding may have been due to large interindividual variations in the response to therapy. Expand
L-Arginine enhances the triglyceride-lowering effect of simvastatin in patients with elevated plasma triglycerides.
It is concluded that L-arginine enhances the effects of simvastatin on lipid metabolism, but it has no triglyceride-lowering effects when given alone. Expand
Effect of simvastatin on high density lipoprotein subfractions and apolipoproteins in Type IIa hypercholesterolemia
SummaryChanges in plasma concentrations of high density lipoproteins (HDL) and triglycerides may partly explain the ability of cholesterol-lowering drugs to decrease the incidence of coronary heartExpand
Evidence of Plasma CoQ10‐Lowering Effect by HMG‐CoA Reductase Inhibitors: A Double‐Blind, Placebo‐Controlled Study
The data show that the treatment with HMG‐CoA reductase inhibitors lowers both total cholesterol and CoQ10 plasma levels in normal volunteers and in hypercholesterolemic patients. Expand
HMG-CoA Reductase Inhibitor Use in the Aged
The available data suggest the efficacy and safety of HMG-CoA reductase inhibitors is similar to that established for younger age groups. Expand
Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits
  • M. Fukami, N. Maeda, +4 authors Y. Tsujita
  • Biology, Medicine
  • Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie
  • 1993
There is no direct correlation between myopathy and the decrease of obiquinone content in skeletal muscles, and animals in the pravastatin-treated group did not show any changes in CK and LDH levels, ubiquin one content in liver and muscles, or in histopathological features of muscle fibers. Expand
A Meta-Analysis Assessing Additional LDL-C Reduction from Addition of a Bile Acid Sequestrant to Statin Therapy.
In patients unable to tolerate an adequate statin dosage, bile acid sequestrants offer a viable alternative with additional LDL-c lowering benefit, and data suggests that combining statin with bile Acid sequestrant increases the percentage change in cholesterol by 16.2 points on average, compared to statin use alone. Expand
Update on the treatment of hypercholesterolemia, with a focus on hmg‐coa reductase inhibitors and combination regimens
Choice of a suitable agent for monotherapy—a bile acid resin, niacin, or an HMG‐CoA reductase inhibitor—may be determined by patient phenotype, and for resistant cases, therapy combined with another agent generally is effective and well tolerated. Expand